



KARDİYOJENİK ŞOK

Fatih KARTALER¹

TANIM

Kardiyojenik şok; hipotansiyona neden olacak durumlar yokluğunda, yeterli intravasküler volüme rağmen kardiyak outputta düşme ve neticesinde doku hipoperfüzyonu ile kendini gösteren son derece mortal bir durumdur. Kardiyojenik şok; erken tespit edilmez ve tedavisine başlanmaz ise doku hipoperfüzyonu nedeniyle, MODS (multiorgan dysfunction syndrome) tablosuna ve neticesinde hastanın hızlıca ölümüne yol açabilir. Kardiyojenik şok tablosunda dirençli sistemik hipotansiyon hemen her zaman gözlenir ve tanı kriterlerinden kabul edilir. Yapılan bazı klinik randomize prospektif çalışmalar neticesinde kardiyojenik şok kriterleri oluşturulmuştur (Tablo 1).

EPİDEMİYOLOJİ

Kardiyojenik şoklu birçok hasta, hastaneye ulaşmadan kaybedildiği için kardiyojenik şokun gerçek insidansını belirlemek oldukça zordur. Ancak yapılan çalışmalarda, son 15 yıl içerisinde kardiyojenik şok nedeniyle yoğun bakım yatış oranı 2 katına çıkarak %4'ten %8'e çıkmıştır (3). Kardiyojenik şokun en önemli nedenlerinden biri olan akut koroner sendrom için; ST segment elevasyonlu miyokard enfarktüsü (STEMI) olan hastalarda kardiyojenik şok oranı %8-9 oranında, ST segment elevasyonu olmayan miyokard enfarktüsü (NSTEMI) hastalarında ise %2,5 seviyesinde izlenmiştir (4-6). Yapılan son çalışmalarda kardiyojenik şoklu hastalarda; hastane içi mortalite iyileşirken, 1, 6 ve 12 aylık mortalite son 20 yılda değişmeden kalmıştır (7,8,9).

¹ Uzm. Dr., Soma Devlet Hastanesi, Kardiyoloji Kliniği, dr.fkartaler@gmail.com

KAYNAKLAR

1. Hochman JS, Sleeper LA, Godfrey E, et al. Should we emergently revascularize Occluded Coronaries for cardiogenic Shock. An international randomized Trial of emergenc PTCA/CABG- Trial Design. *Am Heart J* 1999; 137:313-21.
2. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E (ed). *Heart Disease: A Textbook of Cardiovascular Medicine*. Philadelphia: WB Saunders, 2001:1114-23
3. Puymirat E, Fagon JY, Aegerter P, et al. Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012. *Eur J Heart Fail* 2017;19:192-200.
4. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA* 2005;294:448-54.
5. Goldberg RJ, Spencer FA, Gore JM. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospitalization death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. *Circulation* 2009;119:1211-9.
6. Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. *J Am Coll Cardiol* 2000;36:685-92.
7. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med*. 1999;341:625-634.
8. Thiele H, Zeymer U, Neumann F-J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med*. 2012;367:1287-1296.
9. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol*. 2017;69:278-287.
10. Killip T. Cardiogenic shock complicating myocardial infarction. *J Am Coll Cardiol* 1989;14:47-8
11. Alonso DR, Scheidt S, Post M, Killip T. Pathophysiology of cardiogenic shock: Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlates. *Circulation* 1973;48:588-96.
12. Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. *Circulation* 1997; 96: 122-7
13. Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute coronary syndromes with and without ST segment elevation. *Circulation* 1999; 100: 2067-73.

14. Bauer T, Zeymer U, Hochadel M, et al. Use and outcomes of multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicated by cardiogenic shock (from the EHS-PCI Registry). *Am J Cardiol.* 2012;109:941–946. [PubMed] [Google Scholar]
15. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016;37:2129–2200. [PubMed] [Google Scholar]
16. Lee JM, Rhee T-M, Hahn J-Y, et al. Multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction with cardiogenic shock. *J Am Coll Cardiol.* 2018;71:844–856. [PubMed] [Google Scholar]
17. Van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock—a scientific statement. *Circulation* 2017;136:e232–e268.
18. Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the Cape Horn for trials? *Eur Heart J* 2010;31:1828–1835.
19. Reynolds HR, Hochman JS. Cardiogenic shock. Current concepts and improving outcomes. *Circulation* 2008;117:686–697
20. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. *Circulation.* 2003;107:2998–3002. [PubMed] [Google Scholar]
21. Kohsaka S, Menon V, Lowe AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. *Arch Intern Med* 2005;165:1643–50.
22. Marik PE, Baram M. Noninvasive hemodynamic monitoring in the intensive care unit. *Crit Care Clin* 2007;23:383–400.
23. Neumann FJ, Sousa Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87–165.
24. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;39:119–177.
25. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. *Circulation* 2009; 120:2271–2306.
26. Thiele H, Ohman EM, Desch S, et al. Management of cardiogenic shock. *Eur Heart J* 2015;36:1223–30
27. Nativi-Nicolau J, Selzman CH, Fang JC, et al. Pharmacologic therapies for acute cardiogenic shock. *Curr Opin Cardiol* 2014;29:250–7.

28. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362: 779–89.
29. Tarvasmaki T, Lassus J, Varpula M, et al. Current real life use of vasopressors and inotropes in cardiogenic shock—adrenaline use is associated with excess organ injury and mortality. *Crit Care* 2016; 20:208.
30. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127:e362–425.
31. Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. *J Am Coll Cardiol* 2011;57: 688–96.
32. Tharmaratnam D, Nolan J, Jain A. Management of cardiogenic shock complicating acute coronary syndromes. *Heart* 2013;99:1614–23.